本季度信息
德视佳（股票代码：01846）公布2026年中期业绩，实现营收约4.54亿港元，同比上升20.5%。经调整后（非公认会计准则口径）的净利润约3,801万港元，同比微降1.0%。毛利约1.79亿港元，同比提升14.1%；毛利率约为39.4%。本期经营利润（EBITDA）约为7,910万港元，经营活动现金流为9,102万港元，同比减少10.4%。
公司对进一步扩张和收购带来的成本投入有所增加，销售费用为8,079万港元，约占营收17.8%，比去年同期上升。管理费用为9,257万港元，约占营收20.4%，两项费用率整体同比均出现上升，公司表示主要由于纳入瑞士新业务以及收购相关的一次性费用所致。
业务分项
报告期内，三焦点晶体置换手术需求保持上升，带动整体视力矫正服务收入增长至4.49亿港元。受益于人口老龄化和老花眼需求不受宏观经济波动影响，晶体置换手术收入同比增长16.8%，依托强劲市场需求，成为营收主要动力。同时，屈光性激光手术收入同比提升26.9%，ICL植入术收入增长约22.6%。本期新纳入的瑞士业务整体仍处于整合阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.